Ivana Magovcevic-Liebisch
CIK 1279281 · President and CEO · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DYAX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
100 FORGE ROAD, SUITE 700
WATERTOWN, MA 02472
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QTRX | Director | 15,883 | $2.83 | $44.9K | $0 | 4 | 2026-10-02 |
| ACRV | Director | 9,366 | $1.72 | $16.1K | $0 | 4 | 2026-06-22 |
| Vigil Neuroscience, Inc. (VIGL) Delisted | President and CEO | 0 | $8.05 | $0 | $61.8K | 11 | 2025-08-05 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 6 | 2023-06-30 |
| ABSI | Director | — | $9.45 | — | $0 | 1 | 2022-06-10 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Director | 3,000 | $0.39 | $1.2K | $28.9K | 11 | 2021-12-02 |
| DYAX CORP (DYAX) Delisted | EVP; Chief Operating Officer | 255,984 | — | — | -$972.7K | 20 | 2013-03-29 |
Recent Filings · Page 2 of 6
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-05 | Vigil Neuroscience, Inc. (VIGL) Delisted | Buy (P) | +5,000 | $11.7K | EDGAR |
| 2024-10-03 | QTRX | Grant (A) | +12,800 | $0 | EDGAR |
| 2024-05-07 | Vigil Neuroscience, Inc. (VIGL) Delisted | Mixed | — | $0 | EDGAR |
| 2024-03-01 | Vigil Neuroscience, Inc. (VIGL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-09 | ACRV | Grant (A) | — | $0 | EDGAR |
| 2023-11-20 | Vigil Neuroscience, Inc. (VIGL) Delisted | Buy (P) | +4,000 | $15.0K | EDGAR |
| 2023-06-30 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-03-03 | Vigil Neuroscience, Inc. (VIGL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-10 | ABSI | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.